{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:02:50Z","timestamp":1792785770466,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":450,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institutes of Health Cancer Center","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention Research Institute of Texas","doi-asserted-by":"publisher","award":["RP110584"],"award-info":[{"award-number":["RP110584"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR000371"],"award-info":[{"award-number":["UL1 TR000371"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1093\/annonc\/mdy137","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T15:09:31Z","timestamp":1523977771000},"page":"1869-1876","source":"Crossref","is-referenced-by-count":381,"title":["Selective RET kinase inhibition for patients with RET-altered cancers"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"V.","family":"Subbiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Velcheti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.B.","family":"Tuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ebata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.L.","family":"Busaidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Cabanillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.J.","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Lauriault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Corsi-Travali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Burkard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hamor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Bouhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Winski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.D.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.J.","family":"Brandhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Rothenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Drilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdy137_bb0010","doi-asserted-by":"crossref","first-page":"4846.","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat Commun"},{"issue":"8","key":"10.1093\/annonc\/mdy137_bb0015","doi-asserted-by":"crossref","first-page":"e1005467","DOI":"10.1371\/journal.pgen.1005467","article-title":"Identification of driving ALK fusion genes and genomic landscape of medullary thyroid cancer","volume":"11","author":"Ji","year":"2015","journal-title":"PLoS Genet"},{"issue":"8","key":"10.1093\/annonc\/mdy137_bb0020","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1093\/annonc\/mdy137_bb0025","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"issue":"27","key":"10.1093\/annonc\/mdy137_bb0030","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1038\/sj.onc.1203648","article-title":"Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice","volume":"19","author":"Acton","year":"2000","journal-title":"Oncogene"},{"issue":"11","key":"10.1093\/annonc\/mdy137_bb0035","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1093\/carcin\/bgu158","article-title":"A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis","volume":"35","author":"Saito","year":"2014","journal-title":"Carcinogenesis"},{"issue":"19","key":"10.1093\/annonc\/mdy137_bb0040","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"JCO"},{"issue":"29","key":"10.1093\/annonc\/mdy137_bb0045","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"JCO"},{"issue":"2","key":"10.1093\/annonc\/mdy137_bb0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdy137_bb0055","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdy137_bb0060","article-title":"Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial","author":"Yoh","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1093\/annonc\/mdy137_bb0065","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1158\/1535-7163.MCT-07-2422","article-title":"Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib\/tipifarnib","volume":"7","author":"Hong","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdy137_bb0070","article-title":"ENA-0490 The development of LOXO-292 a potent KDR\/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers","author":"Brandhuber","year":"2016","journal-title":"AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"},{"issue":"7","key":"10.1093\/annonc\/mdy137_bb0075","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/j.jtho.2017.03.007","article-title":"Intracranial and systemic response to alectinib in a patient with RET-KIF5B oncogenic fusion","volume":"12","author":"Velcheti","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy137_bb0080","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00280-014-2578-6","article-title":"Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases","volume":"74","author":"Kodama","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdy137_bb0085","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03; 2010."},{"issue":"2","key":"10.1093\/annonc\/mdy137_bb0090","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdy137_bb0095","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"issue":"15 Suppl","key":"10.1093\/annonc\/mdy137_bb0100","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1158\/1538-7445.AM2015-3581","article-title":"Rapid conversion to resistance, of a colon PDW with ret-fusion, by Ponatinib treatment could potentially be attributed to the introduction of the gate keeper mutation, V804M","volume":"75","author":"Yang","year":"2015","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdy137_bb0105","doi-asserted-by":"crossref","first-page":"9069","DOI":"10.1200\/JCO.2017.35.15_suppl.9069","article-title":"Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers","volume":"35","author":"Drilon","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdy137_bb0110","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1093\/annonc\/mdy137_bb0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2017.10.021","article-title":"Clinical and translational implications of RET rearrangements in non-small cell lung cancer","volume":"13","author":"Ferrara","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy137_bb0120","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1093\/annonc\/mdy137_bb0125","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy137_bb0130","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"issue":"36","key":"10.1093\/annonc\/mdy137_bb0135","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors","volume":"23","author":"Carlomagno","year":"2004","journal-title":"Oncogene"},{"issue":"12","key":"10.1093\/annonc\/mdy137_bb0140","first-page":"1653","article-title":"Clinical activity of alectinib in advanced RET-rearranged non-small cell lung cancer","volume":"17","author":"Lin","year":"2016","journal-title":"J Thorac Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419341043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419341043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/8\/1869\/25505003\/mdy137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T20:40:53Z","timestamp":1660941653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419341043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0923753419341043"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy137","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}